Oncolys BioPharma Inc. (4588.T)
JPY 574.0
(1.59%)
JPY 574.0
(1.59%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.04 Billion JPY | -23.02% |
| 2022 | 2.65 Billion JPY | -38.23% |
| 2021 | 4.29 Billion JPY | 53.48% |
| 2020 | 2.79 Billion JPY | -36.16% |
| 2019 | 4.38 Billion JPY | 27.69% |
| 2018 | 3.43 Billion JPY | -2.73% |
| 2017 | 3.52 Billion JPY | 12.29% |
| 2016 | 3.14 Billion JPY | -21.61% |
| 2015 | 4 Billion JPY | -20.02% |
| 2014 | 5 Billion JPY | -12.08% |
| 2013 | 5.69 Billion JPY | 611.76% |
| 2012 | 800.36 Million JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.88 Billion JPY | -12.04% |
| 2024 Q1 | 2.14 Billion JPY | 5.05% |
| 2023 Q2 | 1.86 Billion JPY | -18.16% |
| 2023 Q1 | 2.28 Billion JPY | -13.97% |
| 2023 Q4 | 2.04 Billion JPY | 14.91% |
| 2023 Q3 | 1.77 Billion JPY | -4.86% |
| 2023 FY | 2.04 Billion JPY | -23.02% |
| 2022 Q4 | 2.65 Billion JPY | -23.28% |
| 2022 FY | 2.65 Billion JPY | -38.23% |
| 2022 Q1 | 3.85 Billion JPY | -10.15% |
| 2022 Q2 | 3.5 Billion JPY | -9.12% |
| 2022 Q3 | 3.45 Billion JPY | -1.41% |
| 2021 Q2 | 5.19 Billion JPY | -4.86% |
| 2021 Q3 | 4.88 Billion JPY | -6.04% |
| 2021 Q4 | 4.29 Billion JPY | -12.11% |
| 2021 FY | 4.29 Billion JPY | 53.48% |
| 2021 Q1 | 5.46 Billion JPY | 95.36% |
| 2020 Q1 | 3.88 Billion JPY | -11.3% |
| 2020 FY | 2.79 Billion JPY | -36.16% |
| 2020 Q2 | 3.51 Billion JPY | -9.4% |
| 2020 Q3 | 2.96 Billion JPY | -15.84% |
| 2020 Q4 | 2.79 Billion JPY | -5.6% |
| 2019 Q1 | 3.31 Billion JPY | -3.49% |
| 2019 Q4 | 4.38 Billion JPY | 1.64% |
| 2019 Q3 | 4.3 Billion JPY | -7.85% |
| 2019 FY | 4.38 Billion JPY | 27.69% |
| 2019 Q2 | 4.67 Billion JPY | 41.26% |
| 2018 Q3 | 3.34 Billion JPY | 19.11% |
| 2018 Q4 | 3.43 Billion JPY | 2.54% |
| 2018 FY | 3.43 Billion JPY | -2.73% |
| 2018 Q2 | 2.8 Billion JPY | -10.81% |
| 2018 Q1 | 3.14 Billion JPY | -10.7% |
| 2017 Q2 | 3.6 Billion JPY | 13.49% |
| 2017 FY | 3.52 Billion JPY | 12.29% |
| 2017 Q4 | 3.52 Billion JPY | -6.61% |
| 2017 Q3 | 3.77 Billion JPY | 4.8% |
| 2017 Q1 | 3.17 Billion JPY | 1.09% |
| 2016 Q4 | 3.14 Billion JPY | -2.81% |
| 2016 Q3 | 3.23 Billion JPY | -9.8% |
| 2016 Q2 | 3.58 Billion JPY | -7.77% |
| 2016 Q1 | 3.88 Billion JPY | -3.05% |
| 2016 FY | 3.14 Billion JPY | -21.61% |
| 2015 Q4 | 4 Billion JPY | -5.83% |
| 2015 Q2 | 4.46 Billion JPY | -4.99% |
| 2015 FY | 4 Billion JPY | -20.02% |
| 2015 Q3 | 4.25 Billion JPY | -4.65% |
| 2015 Q1 | 4.69 Billion JPY | -6.25% |
| 2014 FY | 5 Billion JPY | -12.08% |
| 2014 Q2 | 5.39 Billion JPY | -2.54% |
| 2014 Q1 | 5.53 Billion JPY | -2.83% |
| 2014 Q4 | 5 Billion JPY | -5.55% |
| 2014 Q3 | 5.3 Billion JPY | -1.69% |
| 2013 FY | 5.69 Billion JPY | 611.76% |
| 2013 Q4 | 5.69 Billion JPY | 0.0% |
| 2012 FY | 800.36 Million JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 69.032% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -68.446% |
| GNI Group Ltd. | 62.39 Billion JPY | 96.73% |
| Linical Co., Ltd. | 18.53 Billion JPY | 88.993% |
| Trans Genic Inc. | 9.81 Billion JPY | 79.201% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 63.782% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 70.623% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 64.916% |
| AnGes, Inc. | 28.89 Billion JPY | 92.937% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -135.288% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.702% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -26.073% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 59.762% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 53.089% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 16.123% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 14.021% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 70.555% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -16.509% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 59.875% |
| PeptiDream Inc. | 67.12 Billion JPY | 96.96% |
| Ribomic Inc. | 3.54 Billion JPY | 42.474% |
| SanBio Company Limited | 5.04 Billion JPY | 59.57% |
| Healios K.K. | 15.15 Billion JPY | 86.535% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -65.868% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 32.341% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -38.425% |
| StemRIM | 9.08 Billion JPY | 77.526% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 70.339% |
| FunPep Company Limited | 2.49 Billion JPY | 18.086% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 22.075% |
| Stella Pharma Corporation | 3.82 Billion JPY | 46.59% |
| TMS Co., Ltd. | 3.55 Billion JPY | 42.595% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 64.689% |
| Cuorips Inc. | 6.18 Billion JPY | 67.006% |
| K Pharma,Inc. | 3.31 Billion JPY | 38.423% |
| Takara Bio Inc. | 123.2 Billion JPY | 98.344% |
| ReproCELL Incorporated | 9.05 Billion JPY | 77.458% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 24.849% |
| StemCell Institute Inc. | 6.54 Billion JPY | 68.813% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 70.802% |
| CellSeed Inc. | 2.46 Billion JPY | 17.243% |